EGFR and non-small cell lung carcinoma: Another study conducted by the same group of researchers found that in 27 patients with EGFR-mutated NSCLC receiving second-line osimertinib, there was an increase in methylation of at least one of these nine genes at PD compared with baseline in both plasma cfDNA and paired CTC analysis [137].